In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader (MGD), was shown to normalise multiple atherosclerotic cardiovascular disease (ASCVD) pathogenic drivers. 

Monte Rosa Therapeutics announced the finding along with other positive data from GFORCE-1, a Phase I study evaluating MRT-8102, which being developed for the treatment of inflammatory conditions driven by the NEK7/NLRP3 pathway. 

GFORCE-1 enrolled 108 obese subjects with elevated CVD risk, randomised to MRT-8102 at 5mg, 20mg, or 40mg once daily, or to placebo, for four weeks of dosing and four weeks of follow-up safety evaluation. 

In the trial, MRT-8102 achieved robust and sustained NEK7 degradation, with a median reduction of approximately 80 to 90% observed across all three dose levels.  

Both local drivers of plaque growth and progression and systemic inflammatory biomarkers were substantially reduced following MRT-8102 administration at all three dose levels to levels comparable with baseline values from Phase I healthy volunteers. 

Median values of calprotectin, S100A12, and SAA, which are critical drivers of ASCVD progression, were lowered by 56%, 46%, and 51%, respectively. Also, median values of HMGB1 and IL-1β were elevated at baseline and decreased toward healthy volunteer levels following treatment among subjects with elevated levels. Median reductions were 40% and 37%, respectively, in subjects with levels in the top quartile. 

The thrombogenic factor fibrinogen was reduced by a median of 28% to levels consistent with those in healthy volunteers, while IL-6 and hsCRP, biomarkers of systemic inflammation, were reduced by a median of 54% and 85%, respectively.  

MRT-8102 administration also reduced median lipoprotein(a) by 24%, comparable to PCSK9 inhibitors, and did not increase LDL-C or triglyceride levels. 

Plans for Phase II studies 

“The GFORCE-1 data are highly encouraging and show that MRT-8102 does precisely what we designed it to do: potently and selectively degrade NEK7 and reduce levels of upstream and downstream drivers of residual plaque inflammation and thrombotic risk, and it does so with a differentiated and favourable safety profile,” said Dr Markus Warmuth, Chief Executive Officer of Monte Rosa Therapeutics. “We believe targeting NEK7 at the top of the NLRP3 signalling cascade has the potential to provide a degree of clinical impact across NEK7/NLRP3-driven diseases not achievable by targeting individual downstream cytokines.” 

The company plans to initiate multiple Phase II studies of MRT-8102 in further indications with strong biologic rationale for targeting the NEK7/NLRP3 pathway, including coronary artery disease and residual inflammation, gout and hidradenitis suppurativa.